Involvement of N6-Methyladenosine modifications of long noncoding RNAs in systemic lupus erythematosus: Datasets and Supplementary Materials
收藏资源简介:
Figure 1. Outlines of the SLE m6A methylation. (a) m6A peaks density in patients with SLE and controls. (b) a number of common m6A peaks in patients with SLE and controls. (c) enrichment of m6A peaks along transcripts, each transcript is divided into 5′UTR, CDS and 3′UTR. (d) sequence motif of m6A-containing peak regions. e, heat map of differentially expressed lncRNAs and mRNAs. f, examples of m6A related-lncRNAs peaks. SLE, systemic lupus erythematosus; HC, controls. Figure 2. The expression levels of the m6A-related lncRNAs in patients with SLE and controls. (a) comparison of linc01410 expression between SLE patients and HC; (b) a lower level of Xist in SLE patients compared with HC; (c) a higher level of linc02446 in SLE patients compared with HC; (d) PSMB8-AS1 expression was decreased in SLE patients. SLE, systemic lupus erythematosus; HC, controls. Figure 3 The co-expressed networks of m6A related-lncRNAs and mRNAs. (a) the lincRNA-mRNA co-expression network of linc02446; (b) the lincRNA-mRNA co-expression analysis of PSMB8-AS1. Figure 4. Schematic depicting the mechanisms of m6A methylation modifications to lncRNAs. ‘Writers’, methyltransferases; ‘Erasers’, demethyltransferases; ‘readers’, m6A-binding proteins Table 1 Associations between the expression levels of m6A related lncRNAs and clinical parameters of patients with SLE P value was obtained through t-test or nonparametric Mann-Whitney U test based on data types. Table 2 Correlations between the expression levels of m6A related lncRNAs and quantitative clinical parameters of patients with SLE SLEDAI, the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); C3, Complement C3; C4, Complement C4; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. Table 3. Influences of main medications on m6A related-lncRNAs expression in patients with SLE P value was obtained through t-test or the nonparametric Mann-Whitney U test based on data types.
图1 系统性红斑狼疮(SLE,systemic lupus erythematosus)N6-甲基腺嘌呤(m⁶A)甲基化特征概况。(a) SLE患者与健康对照(HC,controls)的m⁶A峰密度分布;(b) SLE患者与健康对照共有的m⁶A峰数量;(c) 转录本上m⁶A峰的富集分布,每条转录本被划分为5'非翻译区(5'UTR)、编码区(CDS)与3'非翻译区(3'UTR);(d) 含m⁶A的峰区域的序列基序;(e) 差异表达长链非编码RNA(lncRNA)与信使RNA(mRNA)的热图;(f) m⁶A相关lncRNA峰的示例。注:SLE为系统性红斑狼疮,HC为健康对照。 图2 SLE患者与健康对照中m⁶A相关lncRNA的表达水平。(a) SLE患者与健康对照的linc01410表达水平对比;(b) SLE患者体内Xist的表达水平低于健康对照;(c) SLE患者体内linc02446的表达水平高于健康对照;(d) SLE患者体内PSMB8-AS1的表达水平降低。注:SLE为系统性红斑狼疮,HC为健康对照。 图3 m⁶A相关lncRNA与mRNA的共表达网络。(a) linc02446的lncRNA-mRNA共表达网络;(b) PSMB8-AS1的lncRNA-mRNA共表达分析。 图4 m⁶A甲基化修饰调控lncRNA的机制示意图。其中,"Writer"为甲基转移酶,"Eraser"为去甲基化酶,"Reader"为m⁶A结合蛋白。 表1 m⁶A相关lncRNA表达水平与SLE患者临床参数的关联 P值根据数据类型分别通过t检验或非参数曼-惠特尼U检验计算得到。 表2 m⁶A相关lncRNA表达水平与SLE患者定量临床参数的相关性 其中SLEDAI为系统性红斑狼疮疾病活动指数2000(SLEDAI-2K);C3为补体C3;C4为补体C4;ESR为红细胞沉降率;CRP为C反应蛋白。 表3 主要治疗药物对SLE患者m⁶A相关lncRNA表达的影响 P值根据数据类型分别通过t检验或非参数曼-惠特尼U检验计算得到。



